Your browser is no longer supported. Please, upgrade your browser.
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.14 Insider Own5.25% Shs Outstand39.65M Perf Week13.71%
Market Cap933.29M Forward P/E- EPS next Y-1.69 Insider Trans-0.99% Shs Float39.45M Perf Month-5.65%
Income-59.80M PEG- EPS next Q-0.38 Inst Own93.80% Short Float9.01% Perf Quarter30.98%
Sales7.40M P/S126.12 EPS this Y42.50% Inst Trans13.83% Short Ratio4.92 Perf Half Y44.21%
Book/sh5.28 P/B4.46 EPS next Y-21.60% ROA-27.60% Target Price34.33 Perf Year1146.03%
Cash/sh4.91 P/C4.80 EPS next 5Y- ROE-31.40% 52W Range1.87 - 30.17 Perf YTD34.42%
Dividend- P/FCF- EPS past 5Y36.60% ROI-29.70% 52W High-20.58% Beta2.93
Dividend %- Quick Ratio13.90 Sales past 5Y6.20% Gross Margin- 52W Low1181.28% ATR1.90
Employees123 Current Ratio13.90 Sales Q/Q322.20% Oper. Margin- RSI (14)54.84 Volatility6.43% 9.94%
OptionableYes Debt/Eq0.00 EPS Q/Q12.90% Profit Margin- Rel Volume0.30 Prev Close23.55
ShortableYes LT Debt/Eq0.00 EarningsMar 29 AMC Payout- Avg Volume723.15K Price23.96
Recom2.00 SMA205.97% SMA50-2.31% SMA20035.26% Volume161,818 Change1.74%
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-12-21 04:01PM  
Apr-10-21 06:13AM  
Apr-06-21 09:05AM  
Mar-29-21 04:01PM  
Mar-05-21 01:00PM  
Feb-23-21 06:01AM  
Feb-22-21 04:01PM  
Jan-26-21 12:39AM  
Jan-08-21 08:51AM  
Jan-04-21 08:01AM  
Dec-23-20 06:55AM  
Dec-09-20 08:01AM  
Nov-30-20 04:01PM  
Nov-27-20 12:30AM  
Nov-09-20 08:01AM  
Nov-05-20 05:55PM  
Nov-03-20 12:31PM  
Oct-15-20 08:14PM  
Oct-14-20 11:32AM  
Oct-13-20 08:01AM  
Oct-06-20 06:09PM  
Sep-29-20 08:58AM  
Sep-10-20 04:01PM  
Aug-25-20 01:25PM  
Aug-24-20 08:01AM  
Aug-06-20 04:01PM  
Aug-03-20 08:01AM  
Jul-29-20 12:33PM  
Jul-09-20 11:01AM  
Jul-08-20 07:32AM  
Jun-18-20 10:31AM  
Jun-15-20 10:35PM  
Jun-12-20 10:39AM  
Jun-11-20 10:39AM  
Jun-09-20 07:46AM  
Jun-06-20 03:01AM  
May-28-20 03:22PM  
May-25-20 11:30AM  
May-06-20 04:01PM  
Apr-24-20 08:56AM  
Apr-14-20 08:37AM  
Apr-06-20 08:53AM  
Mar-26-20 04:01PM  
Mar-03-20 08:01AM  
Dec-23-19 10:26AM  
Dec-12-19 11:30AM  
Nov-18-19 08:01AM  
Nov-14-19 09:44AM  
Nov-12-19 09:25AM  
Nov-11-19 08:01AM  
Nov-08-19 07:30AM  
Oct-30-19 10:33AM  
Oct-02-19 08:01AM  
Sep-30-19 04:01PM  
Sep-06-19 12:11PM  
Aug-14-19 09:10AM  
Aug-13-19 11:53AM  
Aug-08-19 04:23PM  
Aug-07-19 06:45PM  
Jul-31-19 04:01PM  
Jun-24-19 08:01AM  
Jun-06-19 09:31AM  
Jun-04-19 10:26AM  
Jun-01-19 02:15PM  
May-26-19 05:03PM  
May-14-19 12:36PM  
May-08-19 07:00AM  
May-07-19 06:15PM  
May-02-19 10:32AM  
Apr-06-19 09:30AM  
Apr-02-19 08:00AM  
Apr-01-19 01:00PM  
Mar-20-19 09:30AM  
Mar-13-19 01:19PM  
Mar-08-19 11:04AM  
Mar-07-19 07:44PM  
Feb-22-19 05:50PM  
Feb-20-19 08:25AM  
Feb-14-19 10:45AM  
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wright Richard M.Sr. VP & CCODec 14Option Exercise6.2120,832129,36511,665Dec 16 04:30 PM
Wright Richard M.Sr. VP & CCODec 14Sale18.6120,832387,611208Dec 16 04:30 PM
Young Diane C.SVP, Chief Medical OfficerJun 11Buy4.732,11510,0042,115Jun 12 07:55 AM
Cavanaugh SarahSVP of Corp Affairs & Admin.Jun 10Buy4.831,0505,0721,367Jun 11 07:54 AM
Heath-Chiozzi MargoSVP of Regulatory AffairsJun 09Buy3.001,0003,0051,000Jun 10 07:55 AM
KELER TIBORExecutive VP & CSOJun 09Buy2.995,00014,9547,357Jun 10 07:54 AM
MARINO JAMES JDirectorJun 09Buy3.008,30524,91512,704Jun 10 07:54 AM
Martin Samuel BatesSVP and CFOJun 09Buy3.059,75029,73810,735Jun 10 07:55 AM
Marucci Anthony SPresident & CEOJun 09Buy3.0615,00045,90019,438Jun 10 07:54 AM